ORIGINAL
Quimioembolización transarterial con partículas liberadoras de doxorrubicina frente a quimioembolización transarterial convencional en carcinomas hepatocelulares irresecables: un estudio de eficacia, seguridad y gastos
Trans-arterial Chemoembolization with Doxorubicin-eluting Particles versus Conventional Trans-arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: a Study of Effectiveness, Safety and Costs
J.E. Megías Vericata,
, R. García Marcosb, E. López Brizc, F. Gómez Muñozd, J. Ramos Ruizc, J.J. Martínez Rodrigob, J.L. Poveda Andrésc
Autor para correspondencia
a Department of Pharmacy, Drug Clinical Area, Hospital Universitari i Politècnic La Fe and Instituto de Investigación Sanitaria La Fe, Valencia, Spain
b Department of Radiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
c Department of Pharmacy, Drug Clinical Area, Hospital Universitari i Politècnic La Fe, Valencia, Spain
d Department of Radiology, Hospital Clinic, Barcelona, Spain
Leído
3688
Vecesse ha leído el artículo
3051
Total PDF
637
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 6 | 6 |
| 2025 11 | 0 | 47 | 47 |
| 2025 10 | 0 | 13 | 13 |
| 2025 9 | 4 | 26 | 30 |
| 2025 8 | 3 | 27 | 30 |
| 2025 7 | 5 | 34 | 39 |
| 2025 6 | 8 | 34 | 42 |
| 2025 5 | 2 | 54 | 56 |
| 2025 4 | 0 | 58 | 58 |
| 2025 3 | 1 | 33 | 34 |
| 2025 2 | 1 | 32 | 33 |
| 2025 1 | 4 | 51 | 55 |
| 2024 12 | 1 | 39 | 40 |
| 2024 11 | 0 | 44 | 44 |
| 2024 10 | 2 | 49 | 51 |
| 2024 9 | 1 | 56 | 57 |
| 2024 8 | 0 | 47 | 47 |
| 2024 7 | 1 | 35 | 36 |
| 2024 6 | 0 | 27 | 27 |
| 2024 5 | 0 | 48 | 48 |
| 2024 4 | 3 | 32 | 35 |
| 2024 3 | 0 | 43 | 43 |
| 2024 2 | 0 | 31 | 31 |
| 2024 1 | 2 | 43 | 45 |
| 2023 12 | 1 | 35 | 36 |
| 2023 11 | 0 | 69 | 69 |
| 2023 10 | 0 | 57 | 57 |
| 2023 9 | 2 | 41 | 43 |
| 2023 8 | 2 | 45 | 47 |
| 2023 7 | 0 | 58 | 58 |
| 2023 6 | 1 | 59 | 60 |
| 2023 5 | 0 | 57 | 57 |
| 2023 4 | 1 | 52 | 53 |
| 2023 3 | 3 | 42 | 45 |
| 2023 2 | 1 | 45 | 46 |
| 2022 1 | 1 | 27 | 28 |
| 2022 12 | 0 | 33 | 33 |
| 2022 11 | 1 | 33 | 34 |
| 2022 10 | 0 | 34 | 34 |
| 2022 9 | 0 | 33 | 33 |
| 2022 8 | 0 | 39 | 39 |
| 2022 7 | 0 | 40 | 40 |
| 2022 6 | 0 | 31 | 31 |
| 2022 5 | 0 | 27 | 27 |
| 2022 4 | 0 | 34 | 34 |
| 2022 3 | 1 | 45 | 46 |
| 2022 2 | 0 | 32 | 32 |
| 2021 1 | 0 | 49 | 49 |
| 2021 12 | 0 | 22 | 22 |
| 2021 11 | 0 | 33 | 33 |
| 2021 10 | 0 | 35 | 35 |
| 2021 9 | 0 | 31 | 31 |
| 2021 8 | 0 | 35 | 35 |
| 2021 7 | 0 | 23 | 23 |
| 2021 6 | 0 | 35 | 35 |
| 2021 5 | 0 | 70 | 70 |
| 2021 4 | 0 | 83 | 83 |
| 2021 3 | 0 | 47 | 47 |
| 2021 2 | 0 | 17 | 17 |
| 2020 1 | 0 | 26 | 26 |
| 2020 12 | 0 | 21 | 21 |
| 2020 11 | 1 | 33 | 34 |
| 2020 10 | 3 | 16 | 19 |
| 2020 9 | 1 | 15 | 16 |
| 2020 8 | 0 | 32 | 32 |
| 2020 7 | 0 | 23 | 23 |
| 2020 6 | 0 | 16 | 16 |
| 2020 5 | 2 | 24 | 26 |
| 2020 4 | 0 | 24 | 24 |
| 2020 3 | 0 | 15 | 15 |
| 2020 2 | 0 | 12 | 12 |
| 2020 1 | 0 | 12 | 12 |
| 2019 12 | 0 | 9 | 9 |
| 2019 11 | 0 | 4 | 4 |
| 2019 10 | 0 | 5 | 5 |
| 2019 9 | 0 | 12 | 12 |
| 2019 8 | 0 | 7 | 7 |
| 2019 7 | 0 | 10 | 10 |
| 2019 6 | 0 | 16 | 16 |
| 2019 5 | 0 | 31 | 31 |
| 2019 4 | 0 | 11 | 11 |
| 2019 3 | 2 | 2 | 4 |
| 2019 1 | 1 | 2 | 3 |
| 2018 12 | 3 | 0 | 3 |
| 2018 5 | 9 | 3 | 12 |
| 2018 4 | 26 | 17 | 43 |
| 2018 3 | 22 | 14 | 36 |
| 2018 2 | 24 | 15 | 39 |
| 2018 1 | 18 | 15 | 33 |
| 2017 12 | 21 | 11 | 32 |
| 2017 11 | 20 | 23 | 43 |
| 2017 10 | 15 | 19 | 34 |
| 2017 9 | 21 | 25 | 46 |
| 2017 8 | 33 | 6 | 39 |
| 2017 7 | 41 | 9 | 50 |
| 2017 6 | 39 | 13 | 52 |
| 2017 5 | 30 | 8 | 38 |
| 2017 4 | 25 | 8 | 33 |
| 2017 3 | 43 | 14 | 57 |
| 2017 2 | 20 | 7 | 27 |
| 2016 1 | 32 | 8 | 40 |
| 2016 12 | 31 | 11 | 42 |
| 2016 11 | 62 | 13 | 75 |
| 2016 10 | 0 | 7 | 7 |
| 2016 9 | 0 | 8 | 8 |
| 2016 8 | 1 | 2 | 3 |
| 2016 7 | 2 | 6 | 8 |
| 2016 6 | 0 | 9 | 9 |
| 2016 5 | 0 | 9 | 9 |
| 2016 4 | 3 | 2 | 5 |
| 2016 3 | 3 | 3 | 6 |
| 2016 2 | 7 | 7 | 14 |
| 2015 1 | 3 | 7 | 10 |
| 2015 12 | 5 | 4 | 9 |
| 2015 11 | 16 | 13 | 29 |
Mostrar todo
